Interviews

CAR-T cell treatment can have a number of side effects, with the most serious being cytokine release syndrome, according to David L. Porter, MD, of the University of Pennsylvania Health System. However, there are some promising therapies like interleukin-6 blockers that can reverse this reaction.

Faced with an overwhelming amount of healthcare settings and information, patients with diabetes could find that digital health tools are a powerful resource for managing their illness, according to Heather Zacker, MS, senior director of Care Alliances of Joslin Innovation at Joslin Diabetes Center.

As more organizations begin to issue guidelines for the treatment of rheumatoid arthritis, they will incorporate recommendations to determine whether a drug is working. One option that can help give effective care and streamline patient managements is the use of the Vectra DA test, explained Grace C. Wright, MD, PhD, clinical associate professor of medicine and attending rheumatologist at New York University Langone Medical Center.

Aetna is in the process of transforming from a traditional health insurance company to becoming a healthcare-focused company, in part by emphasizing value-based reimbursement and social determinants of health, said Harold L. Paz, MD, MS, executive vice president and chief medical officer at Aetna.

It can be difficult at times for the Florida Health Care Coalition to meet the needs of every stakeholder, but the patient’s best interest is always at the center, said Karen van Caulil, PhD, president and CEO of the Florida Health Care Coalition. The organization works with task forces and advisory groups to find solutions that put the patient first.

Children need support from their families to fight obesity, as they lack the tools to change their diet and exercise patterns alone, according to Fatima Cody Stanford, MD, MPH, MPA, FAAP, FTOS, of Harvard Medical School and Massachusetts General Hospital. Getting obesity under control in childhood is key to reducing the risk of negative health outcomes later in life.

In order to develop shared decision-making, physicians must build trusting relationships with patients and be mindful of cultural biases, according to Heather Zacker, MS, senior director of Care Alliances of Joslin Innovation at Joslin Diabetes Center. She also encouraged practices to develop a unified direction to ensure incentives are aligned for the entire care team.

Empathy is the root of dignity for patients, and healthcare providers need to consciously adjust their communication styles to demonstrate that empathy, according to Melissa Thompson, MBA, healthcare strategist, patient, and self-advocate. Some examples include not discussing the patient without including them and using inclusive language that brings the patient and provider together.

According to Alex C. Spyropoulos, MD, FACP, FCCP, FRCPC, professor of medicine at the Hofstra Northwell School of Medicine, research on rivaroxaban to prevent thrombosis is moving from determining efficacy to evaluating patient-centered outcomes in a variety of clinical situations, as evidenced by new studies like EINSTEIN-CHOICE and the MARINER trial.

E. Magnus Ohman, MD, FRCPI, FESC, FACC, FSCAI, professor of medicine at Duke University Medical Center, discussed the results of the GEMINI-ACS-1 trial comparing rivaroxaban and aspirin in acute coronary syndrome (ACS), which he and his co-authors presented at the American College of Cardiology 66th Scientific Session. They found no significant differences in the primary endpoints and ischemic outcomes, though further research will be necessary to inform clinical practice.

At the Putting Care at the Center conference, panelists presented their successful models for caring for high-needs patients, which were summarized by Jeffrey Brenner, MD, executive director of the Camden Coalition of Healthcare Providers. These models provided examples of how to scale up innovative approaches to care delivery and interventions.

The EINSTEIN-CHOICE findings presented at the American College of Cardiology 66th Session demonstrated some promising outcomes, showing that rivaroxaban is a viable option for long-term prevention of venous thromboembolism in some patients, said Alex C. Spyropoulos, MD, FACP, FCCP, FRCPC, professor of medicine at the Hofstra Northwell School of Medicine.

A worldwide study of rheumatoid arthritis patients and providers found that they often focus on separate goals, which can lead to a disconnect in communication, according to Allan Gibofsky, MD, professor of medicine and public health at Weill Cornell Medical College and an attending rheumatologist at Hospital for Special Surgery.

If the burden of cost sharing no longer fell on cancer patients, they would be more likely to access care and maintain treatment as prescribed, leading to improved outcomes, according to Samantha Watson, founder and CEO of The Samfund. When faced with high copays, patients are more likely to skip appointments or take only half of their prescribed medications.

The use of biomarkers in immunotherapy has some technical and biological limitations, and is complicated further by the qualitative aspect of cancer treatment, said David Fabrizio, of Foundation Medicine, Inc. A genomic-based solution could help develop more unified quantitative approaches.

At the American College of Cardiology 66th Scientific Session, Eric Peterson, MD, professor of medicine in the division of cardiology at Duke University School of Medicine, presented study findings that showed patients discontinued rivaroxaban less frequently than other anticoagulation agents. These results are important, he said, because regardless of what a clinician prescribes, “it’s the drugs that patients take that make the difference.”

The increased emphasis that the Affordable Care Act and Medicare accountable care organizations (ACOs) placed on prevention is important in reducing the high cost of older patients, especially as the baby boomer generation reached retirement age, explained Mariétou Ouayogodé, PhD, post-doctoral fellow at The Dartmouth Institute for Health Policy and Clinical Practice at the Geisel School of Medicine at Dartmouth.

Jonathan Hirsch, founder and president of Syapse, was working to earn a PhD at Stanford when he noticed that physicians needed better software systems in order to successfully implement precision medicine. He then dropped out of graduate school to found Syapse, a health IT company that provides physician-friendly software.

When caring for patients with diabetes, it’s important for providers to take into account the patient’s culture and how it can affect communication styles and treatment preferences, according to Heather Zacker, MS, senior director of Care Alliances of Joslin Innovation at Joslin Diabetes Center.

The cost of oncology care has increased significantly in recent years, leading employers to worry about how they can provide consistent benefits for employees with cancer and their family members, according to Karen van Caulil, PhD, president and CEO of the Florida Health Care Coalition.

Patients with obesity often face severe stigmatization from healthcare providers, which can discourage them from seeking help, according to Fatima Cody Stanford, MD, MPH, MPA, FAAP, FTOS, of Harvard Medical School and Massachusetts General Hospital. She explained that the “dismal” obesity education in medical schools can lead physicians to judge obese patients unfairly.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo